Equities Analysts Issue Forecasts for CRSP FY2029 Earnings

CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) - Equities research analysts at Brookline Capital Management issued their FY2029 earnings per share estimates for CRISPR Therapeutics in a research note issued to investors on Monday, January 6th. Brookline Capital Management analyst L. Cann forecasts that the company will earn $63.56 per share for the year. The consensus estimate for CRISPR Therapeutics' current full-year earnings is ($5.13) per share.

Other equities research analysts also recently issued reports about the company. Needham & Company LLC reaffirmed a "buy" rating and set a $84.00 price target on shares of CRISPR Therapeutics in a research report on Wednesday, November 6th. Barclays dropped their target price on CRISPR Therapeutics from $59.00 to $55.00 and set an "equal weight" rating on the stock in a report on Wednesday, November 6th. Chardan Capital reissued a "buy" rating and issued a $94.00 price target on shares of CRISPR Therapeutics in a report on Tuesday, December 10th. JMP Securities reaffirmed a "market outperform" rating and set a $86.00 price objective on shares of CRISPR Therapeutics in a research note on Friday, December 20th. Finally, Bank of America decreased their target price on shares of CRISPR Therapeutics from $98.00 to $85.00 and set a "buy" rating for the company in a research note on Tuesday. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating and ten have given a buy rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Hold" and an average price target of $78.38.

CRISPR Therapeutics Stock Down 1.5 %

Shares of NASDAQ:CRSP traded down $0.63 during midday trading on Wednesday, reaching $41.29. The company's stock had a trading volume of 981,717 shares, compared to its average volume of 1,609,082. The stock has a fifty day moving average of $46.63 and a 200 day moving average of $48.94. CRISPR Therapeutics has a twelve month low of $38.20 and a twelve month high of $91.10. The firm has a market capitalization of $3.52 billion, a PE ratio of -14.59 and a beta of 1.68.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last issued its quarterly earnings results on Tuesday, November 5th. The company reported ($1.01) earnings per share for the quarter, topping the consensus estimate of ($1.42) by $0.41. CRISPR Therapeutics had a negative net margin of 118.13% and a negative return on equity of 12.15%. The company had revenue of $0.60 million for the quarter, compared to the consensus estimate of $6.65 million. During the same quarter in the prior year, the company earned ($1.41) EPS.

Insider Transactions at CRISPR Therapeutics

In other news, General Counsel James R. Kasinger sold 1,089 shares of the company's stock in a transaction that occurred on Monday, October 14th. The stock was sold at an average price of $46.28, for a total value of $50,398.92. Following the completion of the sale, the general counsel now directly owns 62,597 shares in the company, valued at $2,896,989.16. This represents a 1.71 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Samarth Kulkarni sold 30,000 shares of CRISPR Therapeutics stock in a transaction that occurred on Monday, November 11th. The stock was sold at an average price of $55.62, for a total value of $1,668,600.00. Following the transaction, the chief executive officer now owns 196,540 shares in the company, valued at approximately $10,931,554.80. The trade was a 13.24 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 50,382 shares of company stock valued at $2,744,179 over the last ninety days. Insiders own 4.10% of the company's stock.

Institutional Investors Weigh In On CRISPR Therapeutics

A number of hedge funds have recently modified their holdings of the company. Northwestern Mutual Wealth Management Co. boosted its holdings in CRISPR Therapeutics by 4.8% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 4,606 shares of the company's stock valued at $249,000 after purchasing an additional 211 shares during the last quarter. Boston Family Office LLC lifted its holdings in CRISPR Therapeutics by 2.2% in the third quarter. Boston Family Office LLC now owns 9,763 shares of the company's stock valued at $459,000 after acquiring an additional 213 shares during the last quarter. Bedell Frazier Investment Counselling LLC grew its position in CRISPR Therapeutics by 0.8% in the third quarter. Bedell Frazier Investment Counselling LLC now owns 26,357 shares of the company's stock worth $1,238,000 after acquiring an additional 218 shares during the period. National Bank of Canada FI increased its stake in CRISPR Therapeutics by 35.0% during the second quarter. National Bank of Canada FI now owns 848 shares of the company's stock worth $46,000 after acquiring an additional 220 shares during the last quarter. Finally, The Manufacturers Life Insurance Company raised its position in CRISPR Therapeutics by 1.9% in the third quarter. The Manufacturers Life Insurance Company now owns 12,477 shares of the company's stock valued at $586,000 after purchasing an additional 231 shares during the period. Hedge funds and other institutional investors own 69.20% of the company's stock.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.